Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users.
Recent progress in enzyme engineering has led to versions of human butyrylcholinesterase (BChE) that hydrolyze cocaine efficiently in plasma, reduce concentrations reaching reward neurocircuity in the brain, and weaken behavioral responses to this drug. Along with enzyme advances, increasingly avid anti-cocaine antibodies and potent anti-cocaine vaccines have also been developed. Here we review these developments and consider the potential advantages along with the risks of delivering drug-intercepting proteins via gene transfer approaches to treat cocaine addiction.
Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester Minnesota, USA. brimijoi@mayo.edu
Stephen
S
Brimijoin
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000235:genetics* / Q000378:metabolism; D003042:Cocaine / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D019970:Cocaine-Related Disorders / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D018014:Gene Transfer Techniques / Q000639:trends; D005814:Genes, Viral / Q000235:genetics; D006801:Humans; D020127:Recovery of Function / Q000276:immunology; D055502:Secondary Prevention
D000911:Antibodies, Monoclonal; D003042:Cocaine